A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Status: | Recruiting |
---|---|
Conditions: | Neurology, Neurology |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/6/2019 |
Start Date: | April 2019 |
End Date: | January 2020 |
Contact: | Momenta General Queries |
Email: | ClinicalTrialInfo@momentapharma.com |
Phone: | +1 617-491-9700 |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281
administered to participants with generalized myasthenia gravis (gMG) who have an
insufficient clinical response to ongoing standard of care therapy.
administered to participants with generalized myasthenia gravis (gMG) who have an
insufficient clinical response to ongoing standard of care therapy.
Participants must be ≥18 years of age with a documented history of Generalized Myasthenia
Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, and no
history of any neurologic disorder other than MG that might interfere with the accuracy of
study assessments.
Additional, more specific criteria are defined in the protocol.
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials